TL;DR
This study investigates the expression of immune checkpoint proteins PD-1 and TIGIT on T cells in the bone marrow (BM) and peripheral blood (PB) of Acute Myeloid Leukemia (AML) patients. They found that these checkpoints are highly co-expressed, particularly in the BM, suggesting a more immunosuppressive environment that could hinder effective immunotherapy. The findings highlight potential therapeutic strategies, especially for elderly AML patients.
What Problem Does This Paper Address?
Immunotherapy, particularly using immune checkpoint inhibitors (ICIs), has revolutionized cancer treatment for many solid tumors. However, its efficacy in Acute Myeloid Leukemia (AML) remains limited. A key challenge is understanding why AML patients don't respond as well to ICIs. This paper focuses on the bone marrow (BM), the primary site of AML, and its unique microenvironment, which may contribute to immune evasion. Specifically, the authors aim to characterize the expression of two critical immune checkpoint proteins, PD-1 and TIGIT, on T cells in both the BM and peripheral blood (PB) of AML patients across different disease stages (diagnosis, remission, relapse) and to explore how age influences this expression. This understanding is crucial for developing more effective ICI-based therapies for AML.
Methods
The researchers employed flow cytometry to analyze the expression of PD-1 and TIGIT on CD4+ and CD8+ T cells. They used a panel of antibodies targeting specific cell surface markers (CD45, CD3, CD4, CD8) and the immune checkpoint proteins of interest (PD-1, TIGIT). Samples were collected from AML patients at different disease stages (de novo diagnosis, complete remission, relapsed/refractory) and from healthy individuals as controls. They also collected samples from both peripheral blood (PB) and bone marrow (BM). Statistical analysis involved correlation, linear regression, and t-tests to compare expression levels between groups and assess age-related trends.
Datasets
The study utilized samples from:
- 38 de novo (DN) AML patients (PB) and 32 (BM)
- 17 complete remission (CR) AML patients (PB) and 21 (BM)
- 10 relapsed-refractory (R/R) AML patients (PB) and 8 (BM)
- 36 healthy donors (PB) and 14 hematopoietic stem cell transplantation donors or iron deficiency anemia patients (BM) as controls.
No new benchmarks were introduced; the study focused on analyzing existing patient sample data.
Key Insights and Ideas
- BM is a "Checkpoint Hotspot": The bone marrow microenvironment in AML patients, especially at diagnosis and relapse, exhibits significantly higher expression of both PD-1 and TIGIT on CD8+ T cells compared to peripheral blood. This suggests the BM creates a more immunosuppressive environment that hinders T cell function.
- Age Matters for Immune Checkpoints: Elderly AML patients (≥60 years) show a higher percentage of PD-1 and TIGIT single-positive CD8+ T cells in both PB and BM. This indicates a greater impairment of T cell function in older individuals, potentially explaining their poorer response to conventional therapies and suggesting a specific vulnerability that could be targeted.
- TIGIT's Persistent Presence: While PD-1 expression can partially recover in complete remission (CR) for some T cell subsets, TIGIT expression on BM CD8+ T cells from DN and R/R patients does not recover with CR. This suggests TIGIT might play a more persistent role in immune suppression in the AML BM.
- Co-expression as a Marker of Exhaustion: The co-expression of PD-1 and TIGIT on CD8+ T cells, particularly in the BM of de novo AML patients, is a strong indicator of T cell exhaustion. This dual blockade might be necessary for effective T cell reactivation.
Key Results
- PD-1 Expression: PD-1 expression was generally higher in PB and BM T cells from de novo (DN) and R/R AML patients compared to healthy individuals. This expression partially recovered in CR patients, except for PB CD8+ T cells.
- TIGIT Expression: TIGIT expression was significantly increased in the BM CD8+ T cell population of DN and R/R AML patients compared to healthy individuals. This increase persisted in CR and R/R patients.
- Age Correlation: Elderly AML patients showed a higher percentage of PD-1 and TIGIT single-positive CD8+ T cells in both PB and BM compared to younger patients.
- BM vs. PB: Both DN and R/R AML patients accumulated a higher frequency of PD-1+ and TIGIT+ CD8+ T cells in the BM compared to their corresponding PB.
- Co-expression: Higher co-expression of PD-1 and TIGIT was observed in PB CD4+ T cells from DN patients and in PB CD8+ T cells from DN and R/R patients. Crucially, increased co-expression was consistently found in the BM CD8+ T cell population across all AML disease stages.
Limitations and Future Work
- Sample Size for CR and R/R: The study notes that statistical significance for co-expression differences in the CR and R/R groups was limited due to smaller patient sample sizes.
- Gene Mutations: The study found no significant differences in PD-1 and TIGIT expression based on FLT3-ITD mutation or complex karyotype. However, they suggest that exploring the relationship with other gene mutations (e.g., TP-53, IDH1/2) would require a larger cohort.
- Functional Heterogeneity: While co-expression of IC proteins is linked to T cell exhaustion, further studies are needed to elucidate the functional heterogeneity of TIGIT+ T cells, especially when co-expressed with other IC proteins or with their competitive activation receptor CD226.
- Prognostic Value: The study suggests that PD-1 expression recovery might be a favorable signal for remission, but whether it can predict prognosis or survival requires further confirmation. Similarly, the prognostic significance of elevated TIGIT expression in BM CD8+ T cells needs to be investigated.
- Therapeutic Strategies: The authors propose that their findings could guide the combined use of anti-PD-1 and anti-TIGIT antibodies, particularly for elderly AML patients. They also suggest exploring strategies to "revive" the immunosuppressive BM microenvironment to improve AML patient survival. Future work should focus on comprehensive assessments of immune checkpoint expression, cytokine secretion, and proliferation capacity of paired PB and BM samples to better understand T cell dysfunction.
Summary updated